Objective-Bilirubin is a potent antioxidant that has been inversely related to cardiovascular disease. There is little information on serum total bilirubin (TB) in relation to atherosclerosis in familial dyslipidemia. We assessed the association between TB and carotid and femoral atherosclerosis in this high-risk group. Approach and Results-We evaluated 464 individuals with familial dyslipidemia (56% men; median age, 48 years), 322 with familial hypercholesterolemia, and 142 with familial combined hyperlipidemia. Carotid and femoral arteries were imaged bilaterally with a standardized ultrasonographic protocol. Mean and maximum intima-media thickness and plaque presence (≥1.2 mm) and height were recorded. Cross-sectional associations between TB and atherosclerosis variables were investigated in multivariable-adjusted models, including lipid values and hypolipidemic drug use. Inflammatory markers (C-reactive protein, total leukocyte count, and lipoprotein[a]) were also determined. Increasing TB levels were associated with decreasing intima-media thickness of all carotid segments (P<0.05, all). TB also related to carotid plaque, present in 78% of individuals, and to plaque burden (≥3 plaques), with odds ratios (95% confidence interval) 0.59 (0.36-0.98) and 0.57 (0.34-0.96) for each increase of 0.5 mg in TB, respectively. Findings were confirmed in a validation cohort of 177 subjects with nonfamilial dyslipidemia. Only the familial combined hyperlipidemia group, with higher inflammationrelated markers, showed an inverse association between TB and femoral plaque height (β=−0.183; P=0.030). 
A therosclerosis is a complex process in which inflammation is believed to play a central role, with oxidative stress and DNA damage induced by oxidized low-density lipoproteins as crucial factors. [1] [2] [3] In fact, inflammatory markers, such as high-sensitivity C-reactive protein (hsCRP), fibrinogen, complement C3, or white blood cell count (WBCC), are prospectively associated with incident cardiovascular events. [4] [5] [6] [7] [8] Conversely, antioxidants are thought to protect against atherosclerosis and coronary artery disease. 9, 10 Bilirubin-an end metabolic product of heme degradation-has demonstrated potent antioxidant and anti-inflammatory properties, both in in vitro and in vivo studies, being particularly effective at suppressing low-density lipoprotein cholesterol oxidation and inhibiting leukocyte migration, consequently hampering the formation of atherosclerotic plaques. [11] [12] [13] In nonselected population, an inverse association between serum total bilirubin (TB) and surrogate measures of cardiovascular disease (CVD), such as intima-media thickness (IMT), 14, 15 coronary artery calcium score, severity of coronary atherosclerosis, [16] [17] [18] arterial stiffness, 19 and flow-mediated vasodilation, 20 has been demonstrated. Beyond this preclinical data, serum TB concentrations have been shown to be inversely associated with the risk of overt CVD in several studies. [21] [22] [23] [24] [25] [26] [27] Information on the role of TB in atherosclerosis among familial dyslipidemias is scarce. In fact, there is only 1 cross-sectional study that showed lower TB levels among patients with familial hypercholesterolemia (FH) and prevalent CVD compared with those with no clinical atherosclerotic disease. 28 To our knowledge, there are no studies addressing the relationship between TB and preclinical atherosclerosis in this group of individuals at high cardiovascular risk. In the present study, we assessed crosssectional associations between TB and atherosclerosis, as evaluated ultrasonographically by IMT and plaque in the carotid and femoral territories, in a group of individuals with familial dyslipidemia, namely FH with genetic diagnosis, FH without known genetic defects (named autosomal dominant hypercholesterolemia [ADH]), and familial combined hyperlipidemia (FCH).
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Subjects' Characteristics
The median age of the study subjects was 48 (25th-75th percentiles; 38-57) years, with a slightly higher prevalence of men (56%). Type 2 diabetes mellitus was present in 4.5%, hypertension in 20.1% and previous CVD in 12.9%. Baseline characteristics according to dyslipidemia diagnosis are shown in Table 1 . As expected, the FCH group had higher body mass index and waist circumference than the other 2 groups (P<0.001 for all comparisons). Regarding laboratory parameters, all lipid values except triglycerides were higher in the FH and ADH groups than in FCH (P<0.05 for all comparisons). Conversely, inflammation-related variables (hsCRP and WBCC) were higher in FCH (P<0.05). FCH subjects also showed more advanced atherosclerosis than the other 2 groups (all carotid IMT-related variables and carotid and femoral plaque burden; P<0.05 for all comparisons). Finally, individuals with previous CVD (n=60) showed more advanced atherosclerosis (carotid plaque presence, 98.3% versus 57.3% and presence of ≥3 carotid plaques, 65.0% versus 23.8% for subjects with and without previous CVD, respectively; P<0.001 for both).
Associations Between TB and Clinical and Laboratory Variables
All but 16 participants with TB >1.2 mg/dL (the cutoff to diagnose Gilbert disease in the absence of liver dysfunction) had levels in the normal range. There were no differences in TB between the different dyslipidemia subtypes (Table 1) . TB was higher in men than in women (0.7 [0.5-0.8] versus 0.5 [0.4-0.7] mg/dL, respectively; P<0.001) but was unrelated to age (Tables I and II in 
Associations Between TB and IMT-Related Variables
In the entire study sample, we found an inverse association between TB and age-and sex-adjusted common carotid artery-IMT and carotid bulb-IMT (both mean and maximum IMT), as well as maximum IMT of any carotid segment (P<0.05 for all comparisons; Table III in the online-only Data Supplement). When TB was divided into tertiles, the age-and sex-adjusted IMT of all the carotid segments increased as TB decreased (P for lineal trend <0.05 for all; Figure 1 ; Figure I in the online-only Data Supplement). No associations were found with femoral IMT. These relationships remained statistically significant after adjusting for other risk factors associated with atherosclerosis and hypolipidemic drug treatment (P<0.05 for all comparisons; 
Associations Between TB and Plaque Burden
In the entire cohort, TB was inversely related to carotid plaque presence (odds ratio, 0.57 [0.37-0.89] for each increment of 0.5 mg/dL in TB; P=0.013; Figure 2 ) and with maximum height of carotid plaques (β=−0.120; P=0.001) in age-and sex-adjusted models. Regarding plaque burden, age-and sexadjusted TB gradually decreased as the number of carotid plaques increased (0.72±0.02, 0.65±0.02, and 0.61±0.03 mg/ dL, for none, 1-2, and ≥3 plaques, respectively) and the number of territories with plaques (0.72±0.03, 0.68±0.02, and 0.64±0.02 mg/dL, for none, 1 territory [carotid or femoral], and both territories; P for lineal trend <0.05 for both; Figure  3 ; Figure II in the online-only Data Supplement, respectively). After adjusting for other risk factors and hypolipidemic drug treatment (fully adjusted models 1 and 2), presence of ≥3 carotid plaques and maximum height of carotid plaques remained inversely associated with TB (P<0.05 for all comparisons; Table 2 ; Table V in the online-only Data Supplement). The inverse association of TB with plaque burden existed irrespective of prior CVD status (Table VI in the online-only Data Supplement).
As with IMT-related variables, the FCH group showed the strongest relationships between TB and plaque measurements. Both in age-and sex-adjusted and in fully adjusted models, it was the only group that showed statistically significant relationships between TB and plaque-related variables (carotid plaque presence, ≥3 carotid plaques, and maximum height of carotid plaques; P<0.05 for all; Figure 2 ; Table 2 ). FCH also showed other relationships with TB not present in the other groups (P<0.05 for interaction). In age-and sex-adjusted models, TB was inversely related with the sum of maximum height of all carotid plaques (β=−0.234; P=0.004) and Data are shown as n (percentage) or median (Q1-Q3). P values for group comparisons are reported. ADH indicates autosomal dominant hypercholesterolemia; ALT, alanine aminotransferase; Apo AI, apolipoprotein AI; Apo B, apolipoprotein B; BMI, body mass index; CCA, common carotid artery; CVD, cardiovascular disease; DBP, diastolic blood pressure; F, femoral; FCH, familial combined hyperlipidemia; FH, familial hypercholesterolemia; GGT, γ-glutamyl transpeptidase; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; ICA, internal carotid artery; IMT, intima-media thickness; LDL, low-density lipoprotein; SBP, systolic blood pressure; TB, total bilirubin; and WBCC, white blood cell count.
*Duration of treatment in years by average statin dose received standardized to simvastatin in milligram. †Data available for n=85 FH, n=42 ADH, and n=77 FCH. ‡Sum of sitosterol+campesterol. Data available for n=269. §Data available for n=269.
maximum height of femoral plaques (β=−0.212; P=0.007), without major changes in fully adjusted models (Table 2) .
Validation Cohort
The validation cohort was made up of 177 individuals with severe, nonfamilial dyslipidemia (polygenic hypercholesterolemia) assessed in our lipid clinic in the same way as individuals of the main cohort. Their median age was 53 (45-60) years, and 51% were men. Type 2 diabetes mellitus was present in 3%, hypertension in 19%, and prior CVD in 6%. Plaques in the carotid and femoral territories were found in 61% and 50%, respectively (35% had plaques in both territories). Other characteristics are shown in Age-and sex-adjusted maximum intima-media thickness (IMT) of any carotid segment according to bilirubin tertiles in 464 individuals with familial dyslipidemia. Total bilirubin (TB) tertiles: T1, ≤0.5 mg/dL; T2, 0.6 to 0.7 mg/dL; and T3, ≥0.8 mg/dL. December 2017 Supplement). These relationships were stronger in individuals with higher levels of inflammation markers (Table XIII in the online-only Data Supplement). TB was unrelated to femoral plaques in this cohort.
Discussion
In our study subjects with familial dyslipidemia, TB was inversely associated with several measures of carotid and femoral atherosclerosis (both IMT and plaque-related variables), independent of other classical and nonclassical cardiovascular risk factors or hypolipidemic drug treatment. Among the dyslipidemia subtypes, FCH disclosed the highest levels of systemic inflammation biomarkers (ie, hsCRP and WBCC) and the strongest associations between TB and plaque burden. To the best of our knowledge, no prior study has related the serum levels of this powerful endogenous antioxidant to carotid and femoral atherosclerosis, including plaque-related variables, in individuals at high cardiovascular risk because of familial dyslipidemia.
TB has previously been shown to be associated with reduced ultrasound-assessed carotid atherosclerosis in few, usually small, studies. 14, 15, 20, 29, 30 All but one 15 used only common carotid artery-IMT as outcome, and none assessed atherosclerosis in the femoral arteries. Also, only 1 prior study conducted in elderly Japanese subjects showed an inverse association between TB and carotid plaque 29 -a better independent predictor of cardiovascular events than IMT 31 recently included in the European Guidelines for CVD prevention as a valid tool for cardiovascular risk reclassification. 32 In the present study, using a large number of individuals at high cardiovascular risk and focusing on both carotid (including common carotid artery, bulb, and internal carotid artery) and femoral territories, we found that TB was inversely and independently associated with both IMT and plaque-related variables in a dose-dependent manner. In fact, in multivariable-adjusted models, an increase of 0.5 mg/dL in TB was associated with a ≈50% chance of harboring a carotid plaque or ≥3 carotid plaques (Table 2; Figure 2 ). Importantly, statistical analyses considered the most known determinants of atherosclerosis and statin treatment-a great modifier of the arterial wall frequently overlooked in previous studies.
Regarding the role of TB in CVD risk in familial dyslipidemia, a single cross-sectional study in FH individuals showed that TB was negatively associated with prevalent CVD in multiple regression models adjusted by common cardiovascular risk factors, but not by smoking status or previous statin treatment, 2 variables closely linked to cardiovascular risk and also related to TB levels in our cohort (Tables I and II in the online-only Data Supplement), which could limit the findings of that study. 28 In our study, focusing not only on genetically diagnosed FH, but also ADH and FCH, we found an inverse association between this simple biomarker and atherosclerosis outcomes (Table 2; Tables III and V in the onlineonly Data Supplement), even after adjusting for the most traditional cardiovascular risk factors (including smoking habit and statin score), as well as the main variables driving the increased cardiovascular risk in this population, namely increased plasma lipid levels. In view of the recent interest Logistic regression models (OR and 95% confidence interval for an increase in 0.5 mg/dL in total bilirubin) for dichotomous dependent variables and lineal regression models (standardized regression coefficients) for logtransformed continuous dependent variables. ADH indicates autosomic dominant hypercholesterolemia; CI, confidence iterval; FCH, familial combined hyperlipidemia; FH, familial hypercholesterolemia; HDL, high-density lipoprotein; LDL, low-density lipoprotein; and OR, odds ratio.
Variables included in fully adjusted model 1 were age, sex, type of dyslipidemia (FCH vs others), smoking habit, alcohol consumption, type 2 diabetes mellitus, hypertension, history of personal cardiovascular disease, body mass index, statin score, actual treatment with bile acid sequestrants or ezetimibe, systolic blood pressure, white blood cell count, γ-glutamyl transpeptidase, alanine aminotransferase, LDL cholesterol, HDL cholesterol, triglycerides, and lipoprotein(a).
in stratifying cardiovascular risk in familial dyslipidemia to better tailor antiatherosclerotic treatment, 33, 34 the use of this simple and widely available biochemical measure could serve this purpose.
Among dyslipidemia subtypes, FCH showed the strongest associations between TB and preclinical atherosclerosis. Only in FCH did TB show statistically significant associations with internal carotid artery-IMT in age-and sex-adjusted models (P=0.077 for interaction between TB *dyslipidemia group in Max IMT-internal carotid artery)-a carotid segment where increased IMT is thought to best predict CVD events. 35 FCH subjects showed increased inflammatory markers compared with FH and ADH, and in them, TB also seemed to confer a greater protection against plaque burden. A potential mechanism is an anti-inflammatory effect of bilirubin. Concurring with our data (Tables I and II in the online-only  Data Supplement) , a large population study showed an inverse association between TB and markers of systemic inflammation (specifically, WBCC). 36 Our findings, and those of others showing an inverse relationship between TB and measures of inflammation in patients with coronary atherosclerosis (ie, hsCRP, neutrophil-to-lymphocyte ratio, and cell distribution width), 17 suggest that besides its antioxidant effects, TB may also exert an anti-inflammatory action. FCH-a complex lipid disorder in which inflammation and oxidative stress may play a role in the lipid phenotype and attendant high cardiovascular risk 37 -could be particularly susceptible to the beneficial effect of TB.
Higher levels of TB could relate to an impairment of the enterohepatic circulation of cholesterol, leading to less biliary cholesterol excretion, hence reduced intestinal cholesterol absorption and ensuing lower blood cholesterol levels, 38 thus explaining, in part, the inverse association between TB and atherosclerosis. However, on one hand, TB and total or lowdensity lipoprotein cholesterol levels were unrelated, and on the other hand, plasma levels of phytosterols (well-validated markers for the efficiency of cholesterol absorption 39 ) and lathosterol (marker of cholesterol synthesis), determined in a subsample of our cohort, also showed no association with TB (Table II in the online-only Data Supplement), suggesting that putative alterations of the enterohepatic circulation of cholesterol played no significant role in our findings. The strength of the genetic, cholesterol-raising defect in our study subjects probably blunted any effect of TB in reducing blood cholesterol.
Our study has some limitations. First, because of the crosssectional design, a causal relationship between TB and IMT or plaque variables cannot be established. It is possible that TB Figure 3 . Age-and sex-adjusted associations of total bilirubin with presence of plaques in ultrasound-assessed arterial territories (carotid or femoral) in the total cohort of individuals with familial dyslipidemia (top) and by dyslipidemia subtype (bottom). ADH indicates autosomal dominant hypercholesterolemia; FCH, familial combined hyperlipidemia; and FH, familial hypercholesterolemia. levels could decrease because of increased consumption during enhanced oxidative stress, rather than being directly associated with atherosclerosis. 40 Second, we have no information on aspirin use in the whole cohort-a potential confounding factor since it has been suggested that this drug raises bilirubin levels through activation of heme oxygenase-1. 41 Aspirin was used by patients with CVD, who had increased IMT and plaques more frequently than individuals in primary prevention, which actually suggests an underestimation of the association. Third, estrogen hormone replacement therapy can influence both lipids and TB levels but, as customary in Spain, 42 the proportion of women treated with estrogens in our cohort was negligible. Finally, seasonal variations in circulating bilirubin could also influence the results 43 ; however, ultrasonography and blood tests were performed throughout the whole year, hence seasonal variation probably played a minor role.
The study also has strengths. One is the relatively large number of individuals with familial dyslipidemia evaluated because there are no previous studies in this high cardiovascular risk population. Most prior studies assessing associations of TB with atherosclerosis focused on IMT, 14, 15, 20, 30 whereas we evaluated carotid plaque-a better independent predictor of cardiovascular events. 31 Furthermore, we adjusted our analyses for all known variables that could influence atherosclerosis, including the statin score-a standardized measure of the strength and duration of statin use frequently overlooked in other studies. Finally, the main associations between TB and carotid atherosclerosis were reproduced in a validation cohort of individuals with nonfamilial (polygenic) dyslipidemia, attesting to the robustness of our findings.
In conclusion, in a cross-sectional study, TB was inversely associated with early (IMT) and advanced (plaque) measurements of atherosclerosis in a population of familial dyslipidemia, independent of other classical or nonclassical cardiovascular risk factors, lipid profile, and statin treatment. This finding was specially pronounced in FCH, in which inflammation and oxidative stress may play an important role in accelerated atherosclerosis. The inverse associations between TB and carotid atherosclerosis were reproduced in a validation cohort of individuals with polygenic hypercholesterolemia. We hypothesize that high serum bilirubin, even in the upper limit of physiological levels, might protect, in part, dyslipidemic individuals from atherosclerosis. Our findings also support using TB as an easy-to-measure, low-cost biomarker of cardiovascular risk in this population, although further studies with a larger sample and a longitudinal design are needed to confirm our results.
